Atezolizumab: all 521 studies that test it
Page 6 of 6. Open to participants first (107), then studies with results posted, then the rest; newest registration first within each.
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
- Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung CancerCompletedNCT02599454Phase 1
- MPDL3280A With Chemoradiation for Lung CancerActive, not recruitingNCT02525757Phase 2
- A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT02500407Phase 1/2
- Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung CancerWithdrawnNCT02495636Phase 2
- MPDL3280A-treatment-IST-UMCGActive, not recruitingNCT02478099Phase 2
- A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02471846Phase 1
- A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLCCompletedNCT02463994Early Phase 1
- A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)CompletedNCT02431208Phase 1
- A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02410512Phase 1
- MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung CancerTerminatedNCT02400814Phase 1
- A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid TumorsCompletedNCT02350673Phase 1
- A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid TumorsCompletedNCT02323191Phase 1
- Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
- A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid TumorsCompletedNCT02304393Phase 1
- Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTerminatedNCT02303951Phase 2
- A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaTerminatedNCT02298153Phase 1
- Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01988896Phase 1
- Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerActive, not recruitingNCT01898117Phase 2
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerSuspendedNCT01810913Phase 2/3
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01375842Phase 1